With an expiration date still more than a year away, here's what the latest details reveal.
GlobalData on MSN
FDA accepts Otsuka’s centanafadine application for ADHD treatment
The Prescription Drug User Fee Act target action date for the NDA is scheduled for 24 July 2026.
It has long been assumed that psychostimulants help those with ADHD by acting on the brain’s attention circuitry. However, ...
The MarketWatch News Department was not involved in the creation of this content.-- Centanafadine is an investigational compound for the treatment of ADHD in children, adolescents ...
Women are driving soaring use of ADHD medication, experts say. Researchers from the University of Oxford highlighted a 20-fold rise in use of drugs to manage the condition among w ...
FDA fast tracks ADHD drug centanafadine, targeting approval by July 24 for treatment across all age groups, based on phase 3 trial results.
ADHD New Zealand spokesperson Darrin Bull joins Mike Hosking to discuss the significant prescription law change that will make ADHD treatment easier to acc ...
From 2022 to 2024, stimulant prescriptions issued in Connecticut increased by 13.2 percent, according to data from the state.
Finding the right ADHD prescription can feel overwhelming at first. With dozens of stimulant and nonstimulant ADHD medications available, many people search for clarity on how these medications work, ...
Health and well-being don't jump to mind when discussing adult ADHD, and neither do poor health, suffering, disability, and ...
Adam Currie - who already had his diagnosis - said his Monday morning appointment was "really smooth".
Some results have been hidden because they may be inaccessible to you
Show inaccessible results